Evolution of the Average Target: Amgen Inc.

Evolution of the Target Price: Amgen Inc.

Changes in Analyst Recommendations: Amgen Inc.

c26ea.BDKPmO80FFk8s9SMnM5Jii5JcyIbmeWRTCtEzfWs85I.NV3iybpfQCFG4bPG5I082morQm1t85bWBRxyp5jju78wR9D13mxVBnjfuw~4722f7eb1899f8f768fabd9c8b744651
20/08 Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating MT
19/08 Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating MT
19/08 Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating MT
18/08 Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating MT
18/08 Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating MT
18/08 Mizuho Securities Adjusts Amgen Price Target to $352 From $303 MT
13/08 Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating MT
13/08 Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating MT
10/08 HSBC Adjusts Price Target on Amgen to $445 From $425, Keeps Buy Rating MT
07/08 Citigroup Adjusts Price Target on Amgen to $405 From $345, Maintains Neutral Rating MT
06/08 Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating MT
05/08 Bernstein Adjusts Price Target on Amgen to $345 From $335, Maintains Market Perform Rating MT
05/08 UBS Adjusts Price Target on Amgen to $440 From $420, Maintains Buy Rating MT
05/08 JPMorgan Adjusts Price Target on Amgen to $350 From $300, Maintains Neutral Rating MT
05/08 Wells Fargo Adjusts Price Target on Amgen to $400 From $390, Maintains Equalweight Rating MT
05/08 Leerink Partners Adjusts Price Target on Amgen to $395 From $355, Maintains Market Perform Rating MT
05/08 TD Cowen Adjusts Price Target on Amgen to $452 From $420, Maintains Buy Rating MT
05/08 Goldman Sachs Adjusts Price Target on Amgen to $450 From $427, Maintains Buy Rating MT
05/08 BMO Capital Adjusts Price Target on Amgen to $450 From $400, Maintains Outperform Rating MT
05/08 Scotiabank Adjusts Price Target on Amgen to $450 From $385, Maintains Sector Outperform Rating MT
05/08 Canaccord Genuity Adjusts Price Target on Amgen to $384 From $366, Maintains Hold Rating MT
05/08 Baird Adjusts Price Target on Amgen to $230 From $215, Maintains Underperform Rating MT
05/08 Oppenheimer Adjusts Price Target on Amgen to $450 From $400, Maintains Outperform Rating MT
05/08 BofA Adjusts Price Target on Amgen to $317 From $312 MT
05/08 RBC Capital Adjusts Price Target on Amgen to $400 From $370, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+6.6%
-0.23%
+4.06%
-0.93%
-3.45%
+24.8%
-12.16%
+0.98%
+5.81%
Average +2.83%
Weighted average by Cap. +3.29%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
442.24USD
Average target price
388.48USD
Spread / Average Target
-12.16%
High Price Target
457.00USD
Spread / Highest target
+3.34%
Low Price Target
230.00USD
Spread / Lowest Target
-47.99%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Piper Sandler
Argus
Morgan Stanley
Mizuho Securities
Cantor Fitzgerald
Daiwa Securities
Barclays
HSBC
Citigroup
Rothschild & Co Redburn
Canaccord Genuity
Bernstein
UBS
JPMorgan Chase
Wells Fargo Securities
Leerink Partners
TD Cowen
Goldman Sachs
BMO Capital
Scotiabank
Baird
Oppenheimer
BofA Securities
RBC Capital Markets
Truist Securities
Guggenheim
Deutsche Bank Securities
DZ Bank
DBS Bank
Jefferies & Co.
Redburn Atlantic
William Blair & Co.
Credit Suisse
DA Davidson
SVB Securities LLC
Cowen
Atlantic Equities
SVB Leerink
JPMORGAN Cory Kasimov
RBC Kennen Mackay
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
442.24USD
Average target price
388.48USD
Spread / Average Target
-12.16%

Quarterly revenue - Rate of surprise